购物车

全部删除
您的购物车当前为空

TNFR2/CD120b/TNFR1B Protein, Human, Recombinant (His)

产品编号 TMPY-01166

TNFR2/CD120b/TNFR1B Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.6 kDa and the accession number is P20333-1.

TNFR2/CD120b/TNFR1B Protein, Human, Recombinant (His)

产品编号 TMPY-01166

TNFR2/CD120b/TNFR1B Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.6 kDa and the accession number is P20333-1.

规格	价格	库存	数量
100 μg	¥ 7,970	In stock
1 mg	¥ 41,850	5日内发货

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

选择批次

资源下载

COA 重组蛋白用户指南

产品信息

生物活性	1. Measured by its ability to inhibit TNF-α mediated cytotoxicity in L-929 mouse fibrosarcoma cells in the presence of the metabolic inhibitor actinomycin D. The ED50 for this effect is typically 0.2-2 μg/ml in the presence of 0.25 ng/mL recombinant human TNF-α. 2. Measured by its binding ability in a functional ELISA. Immobilized Human TNF-alpha at 2 μg/ml (100 μl/well) can bind Human TNFR2/TNFRSF1B His, the EC50 of Human TNFR2/TNFRSF1B His is 2.0-12.0 ng/mL.
产品描述	TNFR2/CD120b/TNFR1B Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.6 kDa and the accession number is P20333-1.
种属	Human
表达系统	HEK293 Cells
标签	C-His
蛋白编号	P20333-1
别名	tumor necrosis factor receptor superfamily, member 1b,TNF-R-II,TNFR80,TNF-R75,TNFR2,TNFR1B,TNFBR,TBPII,p75TNFR,p75,CD120b
蛋白构建	A DNA sequence encoding the extracellular domain (Met1-Asp257) of human TNFRII (NP_001057.1) was expressed with a C-terminal polyhistidine tag. Predicted N terminal: Leu 23
蛋白纯度	≥ 97 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC.
分子量	26.6 kDa (predicted); 40.1 kDa (reducing condition, due to glycosylation)
内毒素	< 1.0 EU/μg of the protein as determined by the LAL method.
缓冲液	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
复溶方法	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
存储	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice.
研究背景	Tumor necrosis factor receptor superfamily, member 1B (TNFRSF1B), also known as Tumor necrosis factor receptor 2 (TNFR2) or CD120b antigen, is a member of the tumor necrosis factor receptor superfamily. TNFR2/CD120b/TNFRSF1B is a member of the TNF-receptor superfamily. This protein and TNF-receptor 1 form a heterocomplex that mediates the recruitment of two anti-apoptotic proteins, c-IAP1 and c-IAP2, which possess E3 ubiquitin ligase activity. Knockout studies in mice also suggest a role of this protein in protecting neurons from apoptosis by stimulating antioxidative pathways. TNFR2/CD120b/TNFRSF1B is not a major contributing factor to the genetic risk of type 2 diabetes, its associated peripheral neuropathy and hypertension and related metabolic traits in North Indians. Tumor necrosis factor receptor superfamily, member 1B (TNFRSF1B) has been reported to be associated with SLE risk in Japanese populations. TNFR2/CD120b/TNFRSF1B serves as a receptor with high affinity for TNFSF2 and approximately 5-fold lower affinity for homotrimeric TNFSF1. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy